Octreotate Lu-177 DOTA Tyr-3

Drug Profile

Octreotate Lu-177 DOTA Tyr-3

Alternative Names: 177Lu-[DOTA0,Tyr3]octreotate; 177Lu-DOTA0-Tyr3-Octreotate; 177Lu-DOTATATE; [Lu-177]-Dota-Tyr3-Octreotate; [Lu-177]-DOTATATE; Lu-DOTATATE; Lutate; Lutathera; Lutetium-177 Octreotate

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator BioSynthema
  • Developer Advanced Accelerator Applications; Centre Hospitalier Universitaire de Quebec
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neuroendocrine tumours

Most Recent Events

  • 31 May 2017 Advanced Accelerator Applications announces intention to resubmit NDA to the US FDA for Neuroendocrine tumours in mid-2017
  • 12 Jan 2017 Updated efficacy data from a phase III NETTER-1 trial in Neuroendocrine tumours released by Advanced Accelerator Applications
  • 21 Dec 2016 Advanced Accelerator Applications receives complete response letter from the FDA for Octreotate Lu-177 DOTA Tyr-3 in Neuroendocrine tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top